Your search for ‘Ropes & Gray’ returned 3,799 results

As discussed back in September, district courts look to PTAB developments in assessing fee awards under 35 U.S.C. § 285.

Today the Patent Trial & Appeal Board (PTAB) added to its growing stockpile of cases that address the meaning of "same or substantially the same prior art or arguments" under 35 U.S.C. § 325(d).

September was another busy month for digital health.

On December 18, 2020, just over one year after proposed regulations were released, the Internal Revenue Service (IRS) and the Department of the Treasury (Treasury)

To help clients across the health care sector assess and transition to value-based payment models, Ropes & Gray's health care group has launched an online hub for articles, webinars, research materials and other valuable resources dedicated to value-based health care, all organized by industry segments and topics: ...

Litigation & enforcement partner Dan Ward, ERISA and benefits partner Josh Lichtenstein, and benefits principal David Kirchner discuss the recent $12 million settlement that has been agreed to in the Oracle 401(k) fee litigation.

Many companies will be publishing their second statements under the UK Modern Slavery Act towards the end of the first half of 2018. Stakeholder expectations are significantly higher this year.

The China Food and Drug Administration (CFDA) has published its proposed amendment of the Medical Device Regulations (MDR), previously known as the State Council Order # 650, for public comments.

On November 21, 2014, China Food and Drug Administration ("CFDA") released a Draft Guidance on Multi-Regional Clinical Trials (Provisional) ("Guidance") for public comments through December 21.

Last month, the European Supervisory Authorities (EBA, ESMA and EIOPA – together, the ESAs) each recently published their Final Reports to the European Commission...

Under EU law, parallel importation is lawful subject to specific derogations that seek to protect human health and industrial and commercial property. Medicinal products are subject...

A summary of the key salient points of the latest legislative proposal to end the special status of all retained EU legislation in the UK domestic law by the end of December 2023 is provided in this alert.

Before the GDPR took effect there was plenty of talk about whether it would usher in a new era of US-style litigation in Europe.

The UK Government continues its efforts to boost investment in high growth companies across the country. A number of the UK's leading VC and growth equity firms...

On September 24, 2024, the G7 nations published, for the first time ever, joint guidance on preventing Russian export control and sanctions evasion...

In contrast to the remarkable levels of deal activity seen in 2021, the last 12 months have been more challenging for private equity investors.

The MHRA launched its 2025 Real-World Evidence (RWE) Scientific Dialogue Programme to enhance regulatory and HTA evaluations. It aims to refine evidence methodologies, support innovation, and prioritize applications addressing public health needs, precision medicine, and innovative study designs.

"Will the regulator investigate or enforce against us?" It's one of the most common questions that clients ask me — and it's still one of the most interesting.